Amisulpride vs. fluoxetine treatment of Chronic Fatigue Syndrome: A pilot study

European Neuropsychopharmacology

Volumn 21, Issue 3, 2011, Pages 282-286

  Pardini, Matteo ^a,b   Guida, Silvia ^a   Primavera, Alberto ^a   Krueger, Frank ^c,d   Cocito, Leonardo ^a   Gialloreti, Leonardo Emberti ^b,e  

^a UNIVERSITY OF GENOA   (Italy)

^b CNAPP   (Italy)

^c GEORGE MASON UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antipsychotic agents; Fatigue

Indexed keywords

AMISULPRIDE; FLUOXETINE;

ADULT; ANXIETY; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; FATIGUE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; MOOD; PAIN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

DOPAMINE ANTAGONISTS; FATIGUE SYNDROME, CHRONIC; FEMALE; FLUOXETINE; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; SULPIRIDE; TREATMENT OUTCOME;

EID: 79251607060     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.10.008     Document Type: Article

References (18)

1. Abbas A.I., Hedlund P.B., Huang X.P., Tran T.B., Meltzer H.Y., Roth B.L. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 2009, 205(1):119-128. (Berl).
2. de Lange F.P., Koers A., Kalkman J.S., Bleijenberg G., Hagoort P., van der Meer J.W., Toni I. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain 2008, 131(Pt 8):2172-2180.
3. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 1994, 121(12):953-959.
4. Green B. Focus on amisulpride. Curr. Med. Res. Opin. 2002, 18(3):113-117.
5. ECDEU Assessment Manual for Psychopharmacology 1976, US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD. W. Guy (Ed.).
6. Hedlund P.B., Sutcliffe J.G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 2004, 25(9):481-486.
7. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46(10):1121-1123.
8. Morriss R.K., Wearden A.J. Screening instruments for psychiatric morbidity in chronic fatigue syndrome. J. R. Soc. Med. 1998, 91(7):365-368.
9. Pae C.U., Marks D.M., Patkar A.A., Masand P.S., Luyten P., Serretti A. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin. Pharmacother. 2009, 10(10):1561-1570.
10. Pardini M., Krueger F., Raymont V., Grafman J. Ventromedial prefrontal cortex modulates fatigue after penetrating traumatic brain injury. Neurology 2010, 74(9):749-754.
11. Rocca P., Fonzo V., Ravizza L., Rocca G., Scotta M., Zanalda E., Bogetto F. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J. Affect. Disord. 2002, 70(3):313-317.
12. Rouillon F., Rahola G., Van Moffaert M., Lopes R.G., Dunia I. Sulpiride in the treatment of somatoform disorders: results of a European observational study to characterize the responder profile. J. Int. Med. Res. 2001, 29(4):304-313.
13. Salyers M.P., Bosworth H.B., Swanson J.W., Lamb-Pagone J., Osher F.C. Reliability and validity of the SF-12 health survey among people with severe mental illness. Med. Care 2000, 38:1141-1150.
14. Vaiva G., Thomas P., Llorca P.M., Dupont S., Cottencin O., Devos P., Mazas O., Rascle C., Steinling M., Goudemand M. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res. 2002, 115(1-2):37-48.
15. Ware J.E., Kosinski M., Keller S.D. A 12 Item Short Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 1996, 34:220-233.
16. Wisniewski S.R., Rush A.J., Balasubramani G.K., Trivedi M.H., Nierenberg A.A. Self-rated global measure of the frequency, intensity, and burden of side effects. J. Psychiatr. Pract. 2006, 12(2):71-79.
17. Xiberas X., Martinot J.L., Mallet L., Artiges E., Canal M., Loc'h C., Maziere B., Paillere-Martinot M.L. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J. Clin. Psychopharmacol. 2001, 21(2):207-214.
18. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67(6):361-370.